Parallax Volatility Advisers
ESPR

Parallax Volatility Advisers’s Esperion Therapeutics ESPR Stock Holding History

Parallax Volatility Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-157,300
Closed -$1M – 3152
2022
Q2 		$1M Buy
+157,300
New +$892K ﹤0.01% 1642
2018
Q4 		– Sell
-30,000
Closed -$1.33M – 3147
2018
Q3 		$1.33M Buy
+30,000
New +$1.38M ﹤0.01% 1172

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Parallax Volatility Advisers's ESPR Position: Q4 2023 in Review

Parallax Volatility Advisers sold out of Esperion Therapeutics (ESPR) in Q4 2023, closing a stake of 10,967 shares — an estimated $10.7K sold.

Parallax Volatility Advisers first reported a position in ESPR in Q1 2017 and held it in 11 quarters. The position peaked at $1.27M in Q4 2018. 132 funds tracked by Wall St. Rank hold ESPR as of Q4 2023.

  • Parallax Volatility Advisers reported no remaining Esperion Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 10,967 Esperion Therapeutics shares in Q4 2023, an estimated $10.7K.
  • Parallax Volatility Advisers first reported a position in Esperion Therapeutics in Q1 2017 and held it in 11 quarters.
  • Parallax Volatility Advisers's Esperion Therapeutics position peaked at $1.27M in Q4 2018.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2023.

Based on Parallax Volatility Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.